Moreover, early data from the trial of treating schizophrenia with emraclidine indicate selectively targeting the CHRM4 may also be a mechanism to reduce psychotic and negative symptom severity (Krystal et al., 2022). This evidence concerns the gene CHRM4 and schizophrenia.